林业发展局提议结束对一些抗体的六个月灵长类动物测试,优先考虑与人有关的替代品。 FDA proposes ending six-month primate tests for some antibodies, favoring human-relevant alternatives.

美国食品和药物管理局建议减少或取消对某些单克隆抗体药物的六个月灵长类动物毒性测试,偏爱计算机模型和实验室生长的组织等与人类相关的替代品. The FDA has proposed reducing or eliminating six-month primate toxicity tests for certain monoclonal antibody drugs, favoring human-relevant alternatives like computer models and lab-grown tissues. 该指导文件草案旨在通过取代过时的动物试验来加快药物研制速度、降低成本和提高准确性,而过时的动物试验往往无法预测人类的反应。 The draft guidance aims to speed drug development, cut costs, and improve accuracy by replacing outdated animal testing, which often fails to predict human responses. 尽管动物倡导者欢迎这一转变,但批评者告诫不要发生可能危及公共健康进步的突然变化。 While animal advocates welcome the shift, critics caution against abrupt changes that could risk public health progress. 该举措与更广泛的安全测试现代化和减少对非人类灵长类动物依赖的努力相一致,尽管最后规则尚待公众评论。 The move aligns with broader efforts to modernize safety testing and reduce reliance on non-human primates, though final rules are pending public comment.